Endothelin receptor antagonists for pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a consequence of acute or chronic disorder of the pulmonary vasculature, which is characterized by increased pulmonary artery pressure as a result of increased pulmonary vascular resistance. The pathophysiology of PAH is characterized by pulmonary vascular va...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bevacqua, R.J., Bortman, G., Perrone, S.V.
Formato: JOUR
Materias:
Ambrisentan
Bosentan
Combination therapy
Endothelin receptor antagonist
Pathophysiological pathways
Pulmonary arterial hypertension
Acceso en línea:http://hdl.handle.net/20.500.12110/paper_18501044_v8_n2_p77_Bevacqua
Aporte de:
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires
id todo:paper_18501044_v8_n2_p77_Bevacqua
record_format dspace
spelling todo:paper_18501044_v8_n2_p77_Bevacqua2023-10-03T16:33:13Z Endothelin receptor antagonists for pulmonary arterial hypertension Bevacqua, R.J. Bortman, G. Perrone, S.V. Ambrisentan Bosentan Combination therapy Endothelin receptor antagonist Pathophysiological pathways Pulmonary arterial hypertension Pulmonary arterial hypertension (PAH) is a consequence of acute or chronic disorder of the pulmonary vasculature, which is characterized by increased pulmonary artery pressure as a result of increased pulmonary vascular resistance. The pathophysiology of PAH is characterized by pulmonary vascular vasoconstriction, smooth muscle cell proliferation, and thrombosis. These changes are a result of an imbalance between vasodilators (prostacyclin, nitric oxide, vasoactive intestinal peptide) and vasoconstrictors (thromboxane A2, endothelin, serotonin), growth inhibitors and mitogenic factors, and antithrombotic and prothrombotic factors. Recent advances in treatment are directed at restoring the balance between these systems. Endothelin receptor antagonists (bosentan, ambrisentan), phosphodiesterase type 5 inhibitors (sildenafil, tadalafil), and prostacylin (epoprostenol, iloprost, treprostinil, beraprost) represent the different classes of medications that are currently used in monotherapy and in combination to treat PAH. The purpose of this review is to provide the reader with an update on the treatment of PAH with antagonists of endothelin receptors. © 2013 Silver Horse. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_18501044_v8_n2_p77_Bevacqua
institution Universidad de Buenos Aires
institution_str I-28
repository_str R-134
collection Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic Ambrisentan
Bosentan
Combination therapy
Endothelin receptor antagonist
Pathophysiological pathways
Pulmonary arterial hypertension
spellingShingle Ambrisentan
Bosentan
Combination therapy
Endothelin receptor antagonist
Pathophysiological pathways
Pulmonary arterial hypertension
Bevacqua, R.J.
Bortman, G.
Perrone, S.V.
Endothelin receptor antagonists for pulmonary arterial hypertension
topic_facet Ambrisentan
Bosentan
Combination therapy
Endothelin receptor antagonist
Pathophysiological pathways
Pulmonary arterial hypertension
description Pulmonary arterial hypertension (PAH) is a consequence of acute or chronic disorder of the pulmonary vasculature, which is characterized by increased pulmonary artery pressure as a result of increased pulmonary vascular resistance. The pathophysiology of PAH is characterized by pulmonary vascular vasoconstriction, smooth muscle cell proliferation, and thrombosis. These changes are a result of an imbalance between vasodilators (prostacyclin, nitric oxide, vasoactive intestinal peptide) and vasoconstrictors (thromboxane A2, endothelin, serotonin), growth inhibitors and mitogenic factors, and antithrombotic and prothrombotic factors. Recent advances in treatment are directed at restoring the balance between these systems. Endothelin receptor antagonists (bosentan, ambrisentan), phosphodiesterase type 5 inhibitors (sildenafil, tadalafil), and prostacylin (epoprostenol, iloprost, treprostinil, beraprost) represent the different classes of medications that are currently used in monotherapy and in combination to treat PAH. The purpose of this review is to provide the reader with an update on the treatment of PAH with antagonists of endothelin receptors. © 2013 Silver Horse.
format JOUR
author Bevacqua, R.J.
Bortman, G.
Perrone, S.V.
author_facet Bevacqua, R.J.
Bortman, G.
Perrone, S.V.
author_sort Bevacqua, R.J.
title Endothelin receptor antagonists for pulmonary arterial hypertension
title_short Endothelin receptor antagonists for pulmonary arterial hypertension
title_full Endothelin receptor antagonists for pulmonary arterial hypertension
title_fullStr Endothelin receptor antagonists for pulmonary arterial hypertension
title_full_unstemmed Endothelin receptor antagonists for pulmonary arterial hypertension
title_sort endothelin receptor antagonists for pulmonary arterial hypertension
url http://hdl.handle.net/20.500.12110/paper_18501044_v8_n2_p77_Bevacqua
work_keys_str_mv AT bevacquarj endothelinreceptorantagonistsforpulmonaryarterialhypertension
AT bortmang endothelinreceptorantagonistsforpulmonaryarterialhypertension
AT perronesv endothelinreceptorantagonistsforpulmonaryarterialhypertension
_version_ 1807323905612840960

Ejemplares similares